In summary, low methylation of DDR genes and TERT promoter mutation are associated with worse prognosis in glioblastoma patients and current studies on DDR inhibitors with and without other cytotoxic or immunological therapies may finally yield benefit especially for the heavily underserved patient population with tumors having an unmethylated MGMT promoter. The gene discussed is TERT; the disease is glioblastoma.